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Abstract
Recombinant human thyrotropin (rhTSH) reduces the activity of radioiodine required to treat multinodular goiter (MNG), but acute 
airway compression can be a life-threatening complication. In this prospective, randomized, double-blind, placebo-controlled 
study, we assessed the efficacy and safety (including airway compression) of different doses of rhTSH associated with a fixed 
activity of 131I for treating MNG. Euthyroid patients with MNG (69.3 ± 62.0 mL, 20 females, 2 males, 64 ± 7 years) received 0.1 
mg (group I, N = 8) or 0.01 mg (group II, N = 6) rhTSH or placebo (group III, N = 8), 24 h before 1.11 GBq 131I. Radioactive iodine 
uptake was determined at baseline and 24 h after rhTSH and thyroid volume (TV, baseline and 6 and 12 months after treat-
ment) and tracheal cross-sectional area (TCA, baseline and 2, 7, 180, and 360 days after rhTSH) were determined by magnetic 
resonance; antithyroid antibodies and thyroid hormones were determined at frequent intervals. After 6 months, TV decreased 
significantly in groups I (28.5 ± 17.6%) and II (21.6 ± 17.8%), but not in group III (2.7 ± 15.3%). After 12 months, TV decreased 
significantly in groups I (36.7 ± 18.1%) and II (37.4 ± 27.1%), but not in group III (19.0 ± 24.3%). No significant changes in TCA 
were observed. T3 and free T4 increased transiently during the first month. After 12 months, 7 patients were hypothyroid (N = 
3 in group I and N = 2 in groups II and III). rhTSH plus a 1.11-GBq fixed 131I activity did not cause acute or chronic changes in 
TCA. After 6 and 12 months, TV reduction was more pronounced among patients treated with rhTSH plus 131I.
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Among many therapeutic options available for volume 
reduction of multinodular goiter (MNG), surgery is the treat-
ment of choice. This approach leads to immediate reduction 
in thyroid volume (TV), as well as to prompt resolution of 
compressive symptoms. Additionally, surgery provides the 
opportunity for a complete histological evaluation (1). The 
radioactive isotope 131I can be used as an alternative when 
surgery is contraindicated or declined by the patient (2). 
For the last two decades, radioiodine has been an effec-
tive therapy. One year after the administration of 131I, the 
reduction in TV ranges from 30 to 40% (2,3), with resolution 
of compressive symptoms in most patients (4). The activ-
ity of radioiodine required for a significant TV reduction is 
positively correlated with the initial TV and inversely cor-
related with the 24-h radioactive iodine uptake (RAIU). In 
many patients with MNG, low RAIU is observed. Since most 
patients with MNG have large goiters and low or normal 
RAIU, large activities of radioactive 131I are usually required. 
For this reason, patients treated with 131I are often subject 
to hospitalization, to greater exposure to radiation, and to 
higher treatment costs (5). 
Recent studies have shown that low doses of recom-
binant human thyrotropin (rhTSH) not only increase RAIU 
(6), but also lead to a more homogenous pattern of uptake 
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(7). Taken together, these properties reduce the 131I activity 
required for the treatment of MNG (8). We have demon-
strated that rhTSH, at doses ranging from 0.005 to 0.2 mg, 
associated with 1.11 GBq 131I, increases RAIU and leads to 
significant decreases in TV, with mild and readily treatable 
adverse effects (9-12).
Acute airway compression causing goiter swelling after 
the administration of rhTSH (13-15) or 131I alone (16,17) 
can be a life-threatening complication within the first few 
days after treatment. Airway compression can be evaluated 
by measuring the tracheal cross-sectional area (TCA). 
However, there are no studies evaluating TCA within the 
first week of treatment with rhTSH plus 131I or 131I alone 
(18). Although treatment of MNG with rhTSH and 131I ap-
pears to be effective and safe, there are few prospective 
controlled studies reported in the literature. 
In the present study, we determined the side effects, 
especially on the airways, of the treatment of euthyroid 
MNG with a fixed activity of 131I activity, 1.11 GBq, after 
the administration of placebo or low doses of rhTSH (0.01 
or 0.1 mg). This is the first study to evaluate the early ef-
fects of combined rhTSH-131I therapy (before 1 week) on 
TCA. In addition, we evaluated the efficacy of the proposed 
treatment in terms of thyroid volume reduction. 
Patients and Methods
Patients
We evaluated 22 patients with MNG (20 females and 
2 males; age 64 ± 7 years). Patients were randomly and 
consecutively selected from the thyroid outpatient clinic of 
the Maringá University, Brazil. All patients had goiters larger 
than 40 mL, and either had a contraindication for surgery, or 
declined surgery. None of the patients had been previously 
submitted to surgery or to treatment with radioiodine. Prior 
to the treatment, malignancy was excluded by ultrasound-
guided fine needle aspiration biopsy of the dominant and/
or suspect nodules and by cytology studies. None of the 
participants had used amiodarone or iodinated contrast in 
the past 12 months. Patients with TSH levels below normal 
were excluded. Normal levels of creatinine, transaminases 
and fasting glucose, as well as normal electrocardiogram, 
excluded the presence of comorbidities. 
Methods 
This was a prospective, randomized, double-blind, 
placebo-controlled study. Patients underwent clinical exami-
nations and blood was drawn before treatment and on days 
0, 3, 10, 30, 90, 180, and 360. On those days, we determined 
total triiodothyronine (T3, chemiluminescence, reference 
range 1.23-3.30 nM, sensitivity 0.29 nM), free thyroxine 
(T4, chemiluminescence, reference range 10.43-23.81 
pM, sensitivity 5.15 pM) and thyroid-stimulating hormone 
(TSH, chemiluminescence, reference range 0.4-4.0 mIU/L, 
sensitivity 0.004 mIU/L). TSH receptor antibody (radioim-
munoassay, reference range <10 IU/L, sensitivity 0.4 U/L), 
antithyroperoxidase antibody (TPOAb, chemiluminescence, 
reference range <10 IU/mL, sensitivity 5 IU/mL) and anti-
thyroglobulin antibody (enzyme immunoassay, reference 
range <20 IU/mL, sensitivity 2.0 IU/mL) were measured on 
days 0, 90, 180, and 360. All assays were performed with 
kits from DPC Diagnostics Products Corporation, USA.
Prior to the treatment, TV was measured by MRI using a 
1.5-Telsa magnetic resonance system (Signa GE, 1.5 Tesla, 
USA), which is an accurate method for assessing TV (19). 
T1-weighted images were obtained from coronal, transverse 
and sagittal sections with 0.5 mm of thickness by using 
a neck coil. The thyroid limits were manually drawn, and 
the thyroid area was calculated by the built-in (dedicated) 
software. Thyroid volume was measured at baseline, and 
2, 7, 180, and 365 days after treatment with 131I.
Tracheal compression was indirectly estimated by 
determining the tracheal cross-sectional area before treat-
ment and on days 2, 7, 180, and 360. TCA was obtained 
by drawing the external border of the trachea, captured 
through T1-weigheted transverse images. 
Basal 24-h RAIU (Pho/Dot scanner, Nuclear Chicago, 
USA) and 131I scintigraphies (dual-headed SPECT camera, 
Elscint-Helix, Israel) were obtained after the oral administra-
tion of 1.85 MBq 131I. Those evaluations were performed 
approximately 30 days before treatment and repeated 24 
h after the administration of rhTSH or placebo. All patients 
were advised to follow a low-iodine diet, starting 2 weeks 
prior to the administration of the diagnostic and therapeutic 
activities of 131I.
For the treatment, a 1.1-mg vial of rhTSH (Thyrogen®, 
Genzyme Corp., USA) was diluted with 1.2 mL sterile water 
for injection, resulting in a 1-mL drawable solution of rhTSH 
concentrated at 0.9 ng/mL. A 1.0-mL aliquot of this solution 
was then diluted with 9 mL sterile water for injection, which 
resulted in a 0.1-mg/mL solution. In order to obtain the 0.01-
mg/mL solution of rhTSH, 1 mL of the 0.1-mg solution was 
diluted with 9 mL sterile water.
Twenty-four hours prior to the administration of 131I 
(day 0), patients were assigned to a previously predefined 
treatment group by simple randomization (20). In that 
procedure, the patients were assigned directly to study 
and control groups, with no intermediate stages. Patients 
in group I received 1.0 mL of this solution (0.1 mg rhTSH) 
intramuscularly, and group II received 1.0 mL of the 0.01-
mg/mL solution. Group III received 1.0 mL isotonic saline. 
On the same day, a tracer activity of 1.85 MBq 131I was 
given to all patients. On the following day (day 1), RAIU 
and scintigraphies were obtained, and 1.11 GBq 131I was 
administered to all participants as a fixed-dose therapeutic 
scheme. 
Adverse effects were evaluated by clinical assessment 
and by frequent measures of thyroid hormone levels. Pa-
tients and investigators were blind to the treatment through-
out the study, including the physicians responsible for the 
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interpretation of the scintigraphies, RAIU and MRI. 
Statistical analysis
The Shapiro-Wilks test was used to assess normality. 
One-way ANOVA with repeated measures was used to 
compare the responses within groups and within time, in 
normally distributed groups. In case of significant differences 
between groups by one-way ANOVA, we used the LSD test 
for multiple comparisons within two groups. For groups 
without normal distribution, within-group comparisons were 
made with the Kruskal-Wallis test. In case of significant dif-
ferences between groups by the Kruskal-Wallis test, we used 
the Mann-Whitney test for multiple comparisons within two 
groups. The Wilcoxon test was used to compare the results 
after treatment with those obtained at baseline. The relative 
changes determined by the treatment were compared within 
the groups by covariance analysis, with the pretreatment 
variable fixed as a co-variable. For dichotomous variables, 
the groups were compared by a model of logistic regres-
sion. Results were considered to be significant 
when P < 0.05. For multiple comparisons by 
non-parametric tests, the P value was adjusted 
by the Bonferroni procedure. 
This trial was reviewed and approved by the 
Ethics Committees of the Universities of Maringá 
and of São Paulo, Brazil, and written informed 
consent was obtained from all patients.
Results
Baseline 
The baseline characteristics of the patients 
at the beginning of the study were not signifi-
cantly different (Table 1). 
Thyroid volume
No acute changes in TV were observed on 
days 2 or 7 in any of the three groups. After 7 
days, TV significantly decreased by 4.0 ± 5.8% 
in group I (P = 0.034) and did not change in 
group II (4.2 ± 8.4%; P = 0.369). In group III, 
TV increased by 5.3 ± 4.6% (P = 0.023). The 
variations in TV were similar between groups II 
and III (P = 0.754), and both were different from 
group I (group I vs group II: P = 0.028; group I 
vs group III: P = 0.009).
After 6 months, TV decreased significantly 
by 28.5 ± 17.6% in group I (P = 0.001), and by 
21.6 ± 17.8% in group II (P = 0.023), but not in 
group III (2.7 ± 15.3%; P = 0.631). The reduc-
tions in TV were similar between groups I and II 
(P = 0.437), and both were different from group 
III (group I vs group III: P = 0.005; group II vs 
group III: P = 0.041). 
After 12 months, a significant decrease TV 
was observed in groups I and II, i.e., 36.7 ± 18.1% (P = 0.008) 
and 37.4 ± 27.1% (P = 0.004), respectively. In group III, the 
changes in TV were not significant compared to baseline 
(19.0 ± 24.3%; P = 0.087). These relative reductions were 
not statistically different among the groups (P = 0.237).  The 
absolute values of TV are given in Table 2. 
Tracheal cross-sectional area
No statistical differences between baseline and post-
treatment TCA values were observed in groups I, II and 
III (ANOVA), and no significant differences in TCA were 
demonstrable on days 2, 7, 180, and 360 after treatment 
(Table 3). 
RAIU
RAIU increased from a median of 15.5% (4.2-55.0%) to 
40.2% (27.8-61.0%; P = 0.025) after 0.1 mg rhTSH in group 
I. In group II, RAIU increased from 27.0% (16.8-34.3%) to 
34.2% (27.6-54.8; P = 0.028). The post-rhTSH RAIU were 
Table 1. Baseline characteristics of the patients studied, before administration 
of 131I plus rhTSH or 131I plus placebo.
Group I Group II Group III
Males:females (N) 1:7 0:6 1:7
Age (years) 62 (44-74) 61 (52-72) 60 (33-72)
TV (mL) 79.7 (41.1-351.5) 58.6 (47.2-126.9) 69.7 (48.2-111.4)
RAIU (%) 15.5 (4.2-55.0) 26.9 (16.8-34.3) 15.2 (3.9-30.6)
TSH (mU/L) 0.91 (0.25-1.61) 0.39 (0.23-1.79) 0.71 (0.21-1.98)
Free T4 (pM) 13.90 ± 2.83 13.51 ± 2.57 13.77 ± 2.96
Total T3 (nM) 2.21 ± 0.36 2.30 ± 0.42 1.95 ± 0.41
Data are reported as means ± SD or median (range). Group I = 0.1 mg rhTSH; 
Group II = 0.01 mg rhTSH; Group III = placebo. rhTSH = recombinant hu-
man thyrotropin; TV = thyroid volume; RAIU = radioactive iodine uptake; T3 
= triiodothyronine; T4 = thyroxine. All patients were treated with a single oral 
activity equal to 30 mCi 131I, preceded by a single subcutaneous injection of 
rhTSH or placebo. There were no statistical differences amongst the three 
groups (ANOVA). 
Table 2. Thyroid volume (in mL) before and after treatment with rhTSH plus 
131I or placebo plus 131I.
Group I Group II Group III
Baseline 79.7 (41.1-351.5) 58.6 (47.2-126.9) 69.7 (48.2-111.4)
Day 2 78.0 (40.5-343.9) 62.8 (47.1-120.8) 75.3 (52.2-106.9)
Day 7 74.9 (42.8-346.9)* 66.0 (47.9-121.7) 75.3 (52.5-109.5)*
6 months 51.3 (20.8-304.7)* 48.7 (23.6-101.3)* 66.3 (42.7-110.7)
12 months 45.8 (20.5-249.5)* 35.2 (22.4-89.2)* 54.5 (25.8-106.7)*
Data are reported as median (range). See Table 1 for explanation of groups. 
rhTSH = recombinant human thyrotropin. *P < 0.05 compared to baseline 
value (LSD test). 
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not different between both groups (P = 0.220). For group 
III (placebo), no changes in RAIU were observed, with 
values from 15.3% (3.9-30.6%) to 16.2% (9.9-31.9%), P 
= 0.889.
Before treatment, heterogeneous thyroid uptake was 
seen in most of the patients with MNG. After rhTSH, a 
more homogeneous pattern of 131I distribution was seen 
in groups I and II. 
Thyroid hormones
At baseline, participants in all groups had similar levels 
of TSH, total T3 and free T4. Since the first post-treatment 
TSH was measured on day 3, we were unable to identify 
the peak levels of TSH. 
After treatment, no statistically significant changes 
in free T4 were observed from day 0 to day 30 in group 
I (P = 0.387). For groups II and III, peak levels of free T4 
were detected on day 30 (group II: 17.63 ± 21.9 pM, P = 
0.037; group III: 20.72 ± 2.83 pM, P < 0.001), which were 
significantly higher than in group I (P = 0.001 for both 
comparisons; Figure 1A). 
Levels of T3 increased in all groups after treatment. 
Group I reached peak levels of T3 on day 3 (2.92 ± 0.81 
nM, P = 0.004). In group II, peak levels of T3 were reached 
on day 30 (2.70 ± -0.46 nM, P = 0.03). In group III, peak 
levels of T3 were observed on day 10 (2.79 ± 0.62 nM, P 
< 0.001; Figure 1B). On the first three days, levels of free 
T4 and total T3 were maintained within the normal range 
in all groups.
Adverse events
Starting on day 90, hypothyroidism was observed in 2 
patients of 8 in group I, 3 of 6 in group II and 1 of 8 in group 
III. After one year, one additional patient in groups I and III 
developed hypothyroidism. 
Mild cervical discomfort, localized pain and palpitations, 
suggesting actinic thyroiditis, were reported by 1 patient in 
each group between days 3 and 10. Propranolol, 80 mg/day, 
and nonsteroidal anti-inflammatory drugs were prescribed 
to those patients, with prompt and complete resolution of 
all symptoms.
Goiter enlargement and/or compressive symptoms 
with respiratory difficulty were reported at baseline by 3 
participants in group I, 2 in group II and 2 in group III. Those 
symptoms were mild, did not cause physical limitations, and 
were resolved without additional interventions in all but 1 
patient, who had a very large goiter at baseline (351 mL). 
One year after treatment, that patient from group I remained 
with the same complaints. After 360 days, in spite of obtain-
ing significant TV reduction and relative improvement of 
the compressive symptoms, the participant still had a very 
Figure 1. Changes in plasma free T4 (A) and T3 (B) after the administration of recombinant human thyrotropin (rhTSH) or placebo and 
radioiodine. See Table 1 for explanation of groups. The box plot indicates the 1 ± SD with the point within each box being mean. The 
size of the rectangle indicates SD. *P < 0.05, compared to baseline (ANOVA).
Table 3. Tracheal cross-sectional area before and after treat-
ment with rhTSH plus 131I or placebo plus 131I.
TCA (mm2) Group I Group II Group III
Baseline 83 (50-171) 130 (97-161) 129 (82-204)
Day 2 103 (54-160) 128 (75-146) 125 (64-209)
Day 7 99 (48-151) 125 (105-145) 121 (75-222)
Day 180 119 (41-149) 128 (108-151) 119 (80-203)
Day 360 120 (40-150) 135 (111-160) 115 (90-150)
Data are reported as median (minimum-maximum). rhTSH = 
recombinant human thyrotropin; TCA = tracheal cross-sectional 
area in mm2. See Table 1 for explanation of groups. There were 
no statistical differences before and after treatment in all groups 
(one-way ANOVA with repeated measures). 
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large goiter (249 mL). Therefore, this patient was referred 
for a new treatment with 131I (without rhTSH). 
One patient in group II and 1 patient in group III did 
not achieve significant TV reductions and remained with 
mild cervical discomfort, without respiratory symptoms. 
However, they preferred clinical observation with no ad-
ditional treatment. 
Before treatment, cosmetic complaints (discomfort due 
to esthetic issues) were reported by 5 patients in group I, 
2 in group II, and 4 in group III. One year after treatment, 
only 1 patient in each group still had cosmetic complaints. 
Therefore, the overall satisfaction rate, regarding cosmetic 
complaints, was 86%.
Antithyroid antibodies
Titers of TSH receptor antibody were negative for all 
groups throughout the study. Three new patients in group 
I developed TPOAb on day 90 and continued positive up 
to day 360, different from groups II and III. The incidence 
of patients with positive antithyroid antibodies is shown in 
Table 4.
Discussion
In the present study, we demonstrated that treatment 
with 131I did not lead to acute airway obstruction, and this 
was independent of the administration of rhTSH. The com-
bination of 131I and rhTSH at 0.01 or 0.10 mg was safe, 
since the incidence of adverse events was similar in all 
groups. In addition, treatment of MNG with 131I and rhTSH 
led to significant TV reduction, superior to placebo, 6 and 
12 months after treatment. 
Our study presents data on TCA 48 h after the admin-
istration of radioiodine, preceded or not by rhTSH for the 
first time. We did not observe significant differences in 
TCA after therapy, either within or between groups. This 
result agrees with the findings from Fast et al. (15) and 
from Bonnema et al. (18). However, in discordance with 
the latter study, we did not observe significant individual 
changes in TCA. Therefore, in our study, we showed that 
treatment with radioiodine does not influence TCA, regard-
less of the use of rhTSH. This could be explained by the 
lack of correlation between TCA and TV, also observed by 
Bonnema et al. (18). 
In patients with MNG, rhTSH increases RAIU and deter-
mines a more homogenous distribution of radioiodine (7,8), 
which allows a reduction in the activity of 131I administered 
(8). Treatment of MNG with 131I alone leads to decreases in 
TV by 30 to 40% after 12 months (2-4). Studies evaluating 
the effects of rhTSH as an adjuvant to fixed activities of 
131I have shown more pronounced TV reductions ranging 
from 34% in the first 6 months (21), to 58% in the first year 
(22). Even with a very low dose, we have demonstrated 
that rhTSH was safe and effective (10). In double-blind, 
randomized, placebo-controlled studies that used adjusted 
Table 4. Incidence of patients with positive titers of antithyroid 
antibodies before and after treatment with rhTSH plus 131I or pla-
cebo plus 131I.
Day 0 Day 90 Day 180 Day 360
TgAb
Group I 2 4 4 3
Group II 1 0 1 1
Group III 1 2 2 1
TPOAb
Group I* 1 4 4 4
Group II 0 1 1 1
Group III 1 1 1 1
TRAb
Group I 0 0 0 0
Group II 0 0 0 0
Group III 0 0 0 0
Data are reported as absolute numbers. See Table 1 for explana-
tion of groups. TRAb = thyrotropin receptor antibody; TPOAb = 
antithyroperoxidase antibody; TgAb = antithyroglobulin antibody. 
*P < 0.05, group I vs groups II and III for TPOAb at 90, 180 and 
360 days (Kruskal-Wallis test).
activities of 131I, TV reductions ranged between 53 (23) and 
62% (24), which were significantly greater in the groups that 
received rhTSH when compared to placebo. 
In our study, TV reduction, compared to baseline, was 
significantly higher among rhTSH-treated patients, at both 
6 and 12 months. Our findings agree with previous studies 
that evaluated goiter reduction with rhTSH and 131I. In those 
studies, goiter reduction was more significant in patients 
treated with rhTSH plus 131I compared to those treated 
with 131I alone. However, in terms of relative changes in 
TV, there was no difference between groups at the 12th 
month. This finding can be attributed to the relatively small 
and heterogeneous sample. 
No significant transient increases in TSH were observed, 
with unexpectedly low peak levels in all groups. Had TSH 
been measured on day 2, higher TSH levels could have been 
observed. Significant peak levels of free T4 were observed 
only in groups II and III. This suggests that the increase in 
free T4 may be attributed more importantly to the actinic 
effect of radioiodine than to the stimulatory effect of rhTSH. 
Significant increases in T3 were observed in all groups, with 
higher levels in the groups that received rhTSH. This sug-
gests that rhTSH leads to more pronounced changes in T3 
than in free T4. The timing of the T3 peaks is explainable by 
the rhTSH (D3 in group I) vs the actinic effect of 131I (D10-
30 in groups II and III). The changes in thyroid hormones 
should be interpreted with caution due to the heterogeneity 
regarding thyroid function at baseline. Nevertheless, the 
mean changes in thyroid hormones remained within normal 
ranges during the study in all groups.
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